AU2015261869A1 - Neonatal microbiome supplementation - Google Patents
Neonatal microbiome supplementation Download PDFInfo
- Publication number
- AU2015261869A1 AU2015261869A1 AU2015261869A AU2015261869A AU2015261869A1 AU 2015261869 A1 AU2015261869 A1 AU 2015261869A1 AU 2015261869 A AU2015261869 A AU 2015261869A AU 2015261869 A AU2015261869 A AU 2015261869A AU 2015261869 A1 AU2015261869 A1 AU 2015261869A1
- Authority
- AU
- Australia
- Prior art keywords
- fetus
- probiotic microorganism
- oral cavity
- probiotic
- neonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 212
- 230000009469 supplementation Effects 0.000 title description 8
- 239000006041 probiotic Substances 0.000 claims abstract description 196
- 235000018291 probiotics Nutrition 0.000 claims abstract description 196
- 230000000529 probiotic effect Effects 0.000 claims abstract description 179
- 210000003754 fetus Anatomy 0.000 claims abstract description 125
- 210000000214 mouth Anatomy 0.000 claims abstract description 118
- 239000000203 mixture Substances 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 49
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 40
- 238000011282 treatment Methods 0.000 claims abstract description 35
- 238000009472 formulation Methods 0.000 claims abstract description 33
- 239000004310 lactic acid Substances 0.000 claims abstract description 20
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 20
- 230000036541 health Effects 0.000 claims abstract description 15
- 230000000968 intestinal effect Effects 0.000 claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims description 68
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 32
- 235000015218 chewing gum Nutrition 0.000 claims description 20
- 206010051606 Necrotising colitis Diseases 0.000 claims description 18
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 18
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 18
- 239000007937 lozenge Substances 0.000 claims description 17
- 208000005107 Premature Birth Diseases 0.000 claims description 14
- 208000002881 Colic Diseases 0.000 claims description 13
- 229940112822 chewing gum Drugs 0.000 claims description 13
- 206010021746 Infantile colic Diseases 0.000 claims description 12
- 241000186660 Lactobacillus Species 0.000 claims description 9
- 208000018773 low birth weight Diseases 0.000 claims description 9
- 231100000533 low birth weight Toxicity 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 239000007910 chewable tablet Substances 0.000 claims description 6
- 208000019206 urinary tract infection Diseases 0.000 claims description 5
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- 208000007565 gingivitis Diseases 0.000 claims description 3
- 229940068682 chewable tablet Drugs 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 39
- 230000001580 bacterial effect Effects 0.000 abstract description 10
- 229940001882 lactobacillus reuteri Drugs 0.000 description 24
- 230000035935 pregnancy Effects 0.000 description 24
- 210000002826 placenta Anatomy 0.000 description 20
- 229960000448 lactic acid Drugs 0.000 description 17
- 238000011321 prophylaxis Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 208000004998 Abdominal Pain Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000008774 maternal effect Effects 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 230000007815 allergy Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 5
- 206010036590 Premature baby Diseases 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 210000001983 hard palate Anatomy 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 210000004195 gingiva Anatomy 0.000 description 4
- 201000000615 hard palate cancer Diseases 0.000 description 4
- 208000013210 hematogenous Diseases 0.000 description 4
- 210000002741 palatine tonsil Anatomy 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229940071604 biogaia Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 206010018785 Gingival infections Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000012369 In process control Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000003896 Myeloperoxidases Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- -1 bacteriocines Chemical class 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 244000005702 human microbiome Species 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000005059 placental tissue Anatomy 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 210000001584 soft palate Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000131694 Tenericutes Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003029 clitoris Anatomy 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 201000005298 gastrointestinal allergy Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000010243 gut motility Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000004680 hydrogen peroxides Chemical class 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000036446 length of gestation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001006 meconium Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462000842P | 2014-05-20 | 2014-05-20 | |
| US62/000,842 | 2014-05-20 | ||
| PCT/EP2015/061181 WO2015177246A2 (en) | 2014-05-20 | 2015-05-20 | Neonatal microbiome supplementation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2015261869A1 true AU2015261869A1 (en) | 2016-11-17 |
Family
ID=53284210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015261869A Abandoned AU2015261869A1 (en) | 2014-05-20 | 2015-05-20 | Neonatal microbiome supplementation |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20170216375A1 (https=) |
| EP (1) | EP3145520A2 (https=) |
| JP (1) | JP2017515881A (https=) |
| KR (1) | KR20170005806A (https=) |
| CN (1) | CN106879253A (https=) |
| AU (1) | AU2015261869A1 (https=) |
| CL (1) | CL2016002732A1 (https=) |
| MX (1) | MX2016015153A (https=) |
| WO (1) | WO2015177246A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11179427B2 (en) | 2013-01-21 | 2021-11-23 | Eth Zurich | Baby food composition comprising viable propionic acid-producing bacteria |
| ES2870425T3 (es) * | 2014-10-29 | 2021-10-27 | Biogaia Ab | Uso de L. reuteri para la prevención o el tratamiento de la disbiosis de microbiota en la vida temprana |
| WO2019118984A2 (en) | 2017-12-15 | 2019-06-20 | Solarea Bio, Inc. | Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome |
| CN112236513B (zh) | 2018-07-24 | 2023-09-19 | 生命大地女神有限公司 | 选择和使用褪黑素支持细菌以减少婴儿绞痛 |
| CA3103356A1 (en) * | 2018-07-24 | 2020-01-30 | Biogaia Ab | Therapeutic methods using bacterial strains which are capable of increasing adenosine levels |
| WO2020028871A1 (en) * | 2018-08-03 | 2020-02-06 | Research Institute At Nationwide Children's Hospital | Prenatal probiotic formulations |
| US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| CA3111795A1 (en) | 2018-09-05 | 2020-03-12 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases |
| EP3870154A4 (en) | 2018-10-22 | 2022-07-27 | Research Institute at Nationwide Children's Hospital | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ANTIBIOTIC-INDUCED PATHOLOGIES USING PROBIOTICS IN BIOFILM STATE |
| EP3979830B1 (en) | 2019-06-03 | 2025-11-26 | Research Institute at Nationwide Children's Hospital | Formulations for the treatment of neurodevelopmental deficiencies induced by necrotizing enterocolitis |
| CA3238788A1 (en) | 2021-11-22 | 2023-05-25 | Eric Michael Schott | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| US20230190834A1 (en) | 2021-12-21 | 2023-06-22 | Solarea Bio, Inc. | Immunomodulatory compositions comprising microbial entities |
| WO2023201092A1 (en) * | 2022-04-14 | 2023-10-19 | Washington University | Prevotella copri formulations and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6872565B2 (en) * | 2003-01-29 | 2005-03-29 | Biogaia Ab | Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries |
| SE528382C2 (sv) * | 2004-10-05 | 2006-10-31 | Probi Ab | Probiotiska lactobacillusstammar för förbättrad vaginal hälsa |
| EP2147678A1 (en) * | 2008-07-21 | 2010-01-27 | Nestec S.A. | Probiotics to increase IgA secretion in infants born by caesarean section |
| EP2295535A1 (en) * | 2009-09-11 | 2011-03-16 | Mead Johnson Nutrition Company | Probiotic material |
| EP2609813A1 (en) * | 2011-12-30 | 2013-07-03 | Nestec S.A. | Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system |
-
2015
- 2015-05-20 MX MX2016015153A patent/MX2016015153A/es unknown
- 2015-05-20 JP JP2016568694A patent/JP2017515881A/ja active Pending
- 2015-05-20 KR KR1020167031451A patent/KR20170005806A/ko not_active Withdrawn
- 2015-05-20 AU AU2015261869A patent/AU2015261869A1/en not_active Abandoned
- 2015-05-20 EP EP15726890.5A patent/EP3145520A2/en not_active Withdrawn
- 2015-05-20 US US15/312,465 patent/US20170216375A1/en not_active Abandoned
- 2015-05-20 CN CN201580025721.0A patent/CN106879253A/zh active Pending
- 2015-05-20 WO PCT/EP2015/061181 patent/WO2015177246A2/en not_active Ceased
-
2016
- 2016-10-27 CL CL2016002732A patent/CL2016002732A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017515881A (ja) | 2017-06-15 |
| WO2015177246A2 (en) | 2015-11-26 |
| US20170216375A1 (en) | 2017-08-03 |
| KR20170005806A (ko) | 2017-01-16 |
| EP3145520A2 (en) | 2017-03-29 |
| WO2015177246A3 (en) | 2016-03-03 |
| MX2016015153A (es) | 2017-03-07 |
| WO2015177246A8 (en) | 2016-01-14 |
| CN106879253A (zh) | 2017-06-20 |
| CL2016002732A1 (es) | 2017-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170216375A1 (en) | Neonatal Microbiome Supplementation | |
| Taylor et al. | Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial | |
| Lenoir-Wijnkoop et al. | Probiotic and prebiotic influence beyond the intestinal tract | |
| Costalos et al. | Enteral feeding of premature infants with Saccharomyces boulardii | |
| MX2012011270A (es) | Pienso para acondicionar la flora intestinal de terneras. | |
| US11274275B2 (en) | Lactobacillus paracasei ET-22 and use thereof | |
| PL189998B1 (pl) | Zastosowanie szczepu Lactobacillus Reuteri | |
| TW200305370A (en) | Vital cell preparations containing lactic acid bacterium as the active ingredient and lactic acid bacterium-containing foods | |
| JP5925274B2 (ja) | 子宮内膜症の予防及び／又は改善剤及びこれを含んでなる飲食品組成物 | |
| Rodríguez et al. | Infectious mastitis during lactation: a mammary dysbiosis model | |
| Tannock | The acquisition of the normal microflora of the gastrointestinal tract | |
| Herman et al. | Prevention of IgE-mediated food allergy: emerging strategies through maternal and neonatal interventions | |
| CN115068591A (zh) | 一种包含骨桥蛋白的益生菌组合物 | |
| JP2023550962A (ja) | アトピー性疾患を予防、遅延、又は改善する方法 | |
| Neu | The developing intestinal microbiome: probiotics and prebiotics | |
| US12582682B2 (en) | Probiotic compositions for the treatment of acne | |
| WO2022161928A1 (en) | Probiotic composition comprising lactobacillus salivarius and bifidobacterium longum and its uses | |
| Yamashiro et al. | Beneficial microbes for premature infants, and children with malignancy undergoing chemotherapy | |
| CN113841737A (zh) | 一株母乳来源罗伊氏乳杆菌防治特应性皮炎的应用 | |
| Amalia | Milk lactoperoxidase system and lactoperoxidase enzyme on the potential of streptococcus Mutans in Children’s saliva | |
| JP2021511822A (ja) | 新規ラクトバチルス・サリバリウス株を含む組成物、及び中耳炎と上気道感染症の予防法／治療法 | |
| Collado et al. | Human Microbiota | |
| McGuire et al. | Probiotics are the new black | |
| RU2514346C1 (ru) | Способ лечения недоношенных новорожденных детей с низкой массой тела | |
| HK40081564A (zh) | 一种包含骨桥蛋白的益生菌组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |